1st Jul 2015 06:57
LONDON (Alliance News) - Imperial Innovations Group PLC on Wednesday said its Veryan Medical portfolio company has enrolled the first subject for its MIMICS-2 study.
The study has been put together to provide data to support a US premarket approval application for Veryan's BioMimics 3D stent system in the US, having already secured European approval.
Veryan is the third-largest portfolio company of Imperial, which invests in technology developed from academic research. Imperial owns a 48.2% stake in the company.
"We are excited by the prospect that MIMICS-2 study will provide further evidence that BioMimics 3D stent offers significant benefits in femoropopliteal use, ultimately leading to approval in the US, thereby expanding the market beyond its current European approval," said Nigel Pitchford, Imperial's chief investment officer.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Imperial Innovations Group